Daisuke Kotani, MD, Ph.D 小谷 大輔· @DaisukeKotani · X·· 2 days agoScore90
Body · original
#ESMO26 | LBA79
Second interim analysis from Ph3 HERIZON-GEA-01
Overall survival
▪️Zani + chemo vs Tra + chemo: 22.9 vs 19.6 mo, HR 0.76, p=0.0088
▪️Zani + Tis + chemo vs Zani + chemo: 27.0 vs 22.9 mo, HR 0.81, p=0.0502
@myESMO @OncoAler
2328 views · 10 likes · 9 reposts · 0 replies
Conference abstracts
LBA79matched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01
https://esmocongress.esmo.orgSource: Daisuke Kotani, MD, Ph.D 小谷 大輔 · x.com